Pilot study of relative bioavailability of two oral formulations of ketoprofen 25 mg in healthy subjects. A fast-dissolving lyophilized tablet as compared to immediate release tablet

Drug Development and Industrial Pharmacy

Volumn 33, Issue 5, 2007, Pages 505-511

  Ahmed, I S ^a   Fatahalla, F A ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

Author keywords

Bioavailability; Fast dissolving tablet; Ketoprofen; Lyophilized tablet

Indexed keywords

KETOPROFEN;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; HUMAN; HUMIDITY; IMMEDIATE RELEASE TABLET; INTERMETHOD COMPARISON; LYOPHILIZED TABLET; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; HALF-LIFE; HUMANS; HUMIDITY; KETOPROFEN; MALE; SOLUBILITY; TABLETS;

EID: 34249301019     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040601150237     Document Type: Article

References (23)

1. Ahmed, I. S., Nafadi, M. M., & Fatahalla, F. A. (2006). Formulation of a fast-dissolving ketoprofen tablet using freeze-drying in blisters technique. Drug Dev. Ind. Pharm., 32, 1-6.
2. Airaksinen, O. (1993). Ketoprofen 2.5% gel versus placebo gel in the treatment of acute soft tissue injuries. Int. J. Clin. Pharm., 31, 561-563.
3. Barbanoj, M. J., Antonijoan, R. M., & Gich, I. (2001). Clinical pharmacokinetics of dexketoporfen. Clin. Pharmacokinet., 40, 245-262.
4. Chi, S. C., & Jun, H. W. (1991). Release rates of ketoprofen from poloxamer gels in a membraneless diffusion cell. J. Pharm. Sci., 80, 280-283.
5. Debruyne, D., de Hurault Ligny, B., Ryckelynck, J. P., Albessard, F., & Moulin, M. (1987). Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. Clin. Pharmacokinet., 12, 214-221.
6. Fossgreen, J. (1976). Ketoprofen. A survey of current publications. Scand. J. Rheumatol., 14, 7-32.
7. Ishizaki, T., Sasaki, T., Suganuma, T., Horai, Y., Chiba, K., Watanabe, M., Asuke, W., & Hoshi, H. (1980). Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. Eur. J. Clin. Pharmacol., 18, 407-414.
8. Jachowicz, R., Nurnberg, E., Pieszczek, B., Kluczykowska, B., & Maciejewska, A. (2000). Solid dispersion of ketoprofen in pellets. Int. J. Pharm., 206, 13-21.
9. Kantor, T. G. (1986). Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy, 6, 93-103.
10. Keinänen-Kiukaanniemi, S., Similä, S., & Kouvalainen, K. (1980). Oral antipyretic therapy evaluation of the propionic acid derivatives, ibuprofen, ketoprofen, fenoprofen and naproxen. Paediatr. Padol., 15, 239-244.
11. Kokki, H., Karvinen, M., & Jekunen, A. (2002). Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. Acta Anaesthesiol. Scand., 46, 194-198.
12. Kokki, H., Nikanne, E., & Ahonen, R. (2000). The feasibility of pain treatment at home after adenoidectomy with ketoprofen tablets in small children. Paediatr. Anaesth., 10, 531-535.
13. Kokki, H., Tuomilehto, H., & Karvinen, M. (2001). Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. Eur. J. Clin. Pharmacol., 57, 643-647.
14. Le Liboux, A., Teule, M., Frydman, A., Oosterhuis, B., & Jonkman, J. H. (1994). Effect of diet on the single- and multiple-dose pharmacokinetics of sustained-release ketoprofen. Eur. J. Clin. Pharmacol., 47, 361-366.
15. Nievel, J. G., Havard, C. W., Mitchell, P., Gudgeon, A., & Kaye, C. M. (1987). Effect of meal size and composition on the bioavailability of ketoprofen (Oruvail). Xenobiotica, 17, 487-492.
16. Nikanne, E., Kokki, H., & Tuovinen, K. (1999). Postoperative pain after adenoidectomy in children. Br. J. Anaesth., 82, 886-889.
17. Rifai, N., Lafi, M., Sakamto, M., & Law, T. (1997). Measurement of plasma ketoprofen by a rapid high-performance liquid chromatography assay. Ther. Drug Monit., 19, 175-178.
18. Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm., 15, 657-680.
19. th Ed., Appleton & Lange, Stamford, Connecticut, p. 385.
20. Solanker, A. K., & Jagtap, A. G. (2005). Chronobiological and chronopharmacological studies of ketoprofen and its solid dispersion form using adjuvant arthritis model in rats. Indian J. Exp. Biol., 43, 46-52.
21. Stiegler, S., Birkel, M., Jost, V., Lange, R., Lücker, P. W., & Wetzelsberger, N. (1995). Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets. Meth. Find. Exp. Clin. Pharmacol., 17, 129-134.
22. Topalogu, Y., Yener, G., & Gonullu, U. (1999). Inclusion of Ketoprofen with Skimmed Milk by Freeze-Drying. Il Farmaco, 54, 648-652.
23. US Food and Drug Administration. (1993). In vivo bioequivalence guidance, Pharmacopeial Forum, 19, 6501-6508.